Peptide therapy TikTok claims: what the science actually supports

What did @tiana.prime actually say?

Tiana is doing something genuinely reasonable: she is getting bloodwork done regularly and planning to track it alongside peptide use. She mentions being about four weeks into peptide use, currently taking MT2, RETA, and GHK-Cu (inconsistently, due to stock issues), and considering adding selank. Her stated goals are health optimization, mood stability, brain fog reduction, and mental clarity. No dramatic cure claims, no wild dosing advice. Mostly she is setting up a personal experiment and sharing it publicly.

That said, she is using several compounds that carry real regulatory and safety questions, and her characterization of selank as something that simply "helps your nervous system" and "mood stability" leaves out a lot of important context that her 5,700 viewers probably need.

Does the science back this up?

It depends heavily on which peptide you are asking about. Selank has the most interesting research base of what she mentions, but that research is almost entirely Russian, mostly preclinical, and not replicated in large Western randomized controlled trials. GHK-Cu has a legitimate wound-healing and anti-inflammatory research profile. MT2 is more complicated and carries real risks.

On selank specifically: it is a synthetic analogue of tuftsin, a naturally occurring immunomodulatory peptide. Russian studies, including work by Semenova et al. (2010, Neurochemical Journal), suggest anxiolytic and nootropic effects in animal models. A small number of human studies out of Russian research institutes report reduced anxiety and improved cognitive function, but these have not been independently replicated in peer-reviewed Western journals to a standard that would satisfy the FDA or EMA. Calling it a nervous system support compound is not wrong exactly, but it overstates the certainty of what we know.

GHK-Cu research by Pickart and Margolina (2018, Cosmetics) does support roles in tissue repair and inflammation modulation, though most robust data is in vitro or animal-based. MT2 (melanotan II) has a far messier profile, which is addressed below.

What did they get wrong (or right)?

Credit where it is due: tracking bloodwork over time while introducing new compounds is exactly the kind of harm-reduction approach that responsible self-experimenters should follow. She does not make disease claims. She is appropriately cautious about selank, saying she will "wait a while" before adding it. That is more restraint than most peptide content creators show.

What she gets wrong, or at least glosses over, is MT2. Melanotan II is not approved by the FDA or any major regulatory body. It acts as a non-selective melanocortin receptor agonist. Side effects documented in the literature include nausea, spontaneous erections, facial flushing, and, more seriously, reported changes in existing moles and potential links to melanoma progression in predisposed individuals (Bandarchi et al., 2009, Journal of Clinical Oncology, case reports). The Therapeutic Goods Administration in Australia has issued specific warnings. Tiana mentions MT2 without any of this context. That is a meaningful omission for a public video.

RETA is likely a reference to retatrutide or a similar GLP-1/GIP/glucagon tri-agonist compound. If so, it is an investigational drug currently in clinical trials (Eli Lilly), not an approved therapy, and access outside of trials raises serious questions about sourcing and purity that she does not address.

What should you actually know?

If you are watching this and thinking about replicating Tiana's stack, a few things matter more than the peptide names themselves. First, sourcing is everything with unregulated peptides. Purity data from third-party certificate of analysis testing is not optional, it is basic safety practice. Second, the combination of multiple peptides with overlapping hormonal or neurological activity is not something that has been studied in humans in any systematic way. We genuinely do not know what stacking MT2, GHK-Cu, and selank does over months.

Third, on selank specifically: it is not scheduled in most countries and has a relatively benign side effect profile in available research, but "relatively benign in small Russian trials" is not the same as "proven safe for long-term use." The research simply does not exist yet at the scale needed to say that confidently.

Tracking your own bloodwork is genuinely good practice. But bloodwork alone will not catch every risk these compounds carry, particularly neurological or dermatological changes that require clinical evaluation, not just a metabolic panel.